

**Sheep Anti-Human TAFI
(Thrombin Activatable Fibrinolysis
Inhibitor)
Affinity Purified IgG
0.5 mg**

Catalogue: SATAFI-AP
Lot: SAMPLE
Expiry date: **/****
Store at -10 to -20°C.

For Research Use Only ~ Not for use in diagnostic procedures.

DESCRIPTION OF TAFI (proCPU)

TAFI (Thrombin Activatable Fibrinolysis Inhibitor), also referred to as plasma procarboxypeptidase-B, procarboxypeptidase-U and R, circulates in plasma as a zymogen with a mass of 58,000 daltons (1-6). Proteolytic activation of TAFI yields an N-terminally derived activation peptide and the C-terminal portion corresponding to the metalloprotease, activated TAFI (TAFIa). TAFIa exhibits exopeptidase activity with carboxypeptidase B-like substrate specificity capable of catalyzing the hydrolysis of C-terminal lysine and arginine residues. Cleavage of these residues on fibrin by TAFIa attenuates clot lysis by inhibiting the formation of the ternary activation complex comprising fibrin cofactor, tPA and plasminogen, thereby inhibiting plasmin generation. Although TAFI can be activated by various proteases including thrombin and plasmin, the physiological activator is proposed to be the complex thrombin-thrombomodulin since the rate of activation is stimulated 1250-fold compared to thrombin alone (4). However, the rate of TAFI activation is highly dependant upon its plasma concentration. Since TAFIa apparently plays a key role in connecting coagulation and fibrinolysis and significantly increases clot stability, determination of plasma concentration of ATFI is likely crucial to assess its subsequent potential antifibrinolytic effects¹⁻⁶.

REFERENCES and REVIEWS

1. Eaton, D.L., Malloy, B.E., Tsai, S.P., Henzel, W., Drayna, D., Isolation, Molecular Cloning and Partial Characterization of a Novel Carboxypeptidase B from Human Plasma, *J.Biol. Chem.* **266**:21833-21838, 1991.
2. Hendriks, D., Scharpe, S., van Sande, M., Lommaert, M.P., Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. *J.Clin.Chem.Clin.Biochem.* **27**:277-285, 1989.

3. Campbell W., Okada, J. An Arginine specific carboxypeptidase generated in blood during coagulation of inflammation which is unrelated to carboxypeptidase N or its subunits. *Biochem.Biophys.Res.Comm.* **162**:933-939, 1989.
4. Bajzar, L., Morser, J., Nesheim, M.E. TAFI or procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex, *J.Biol.Chem.* **271**:16603-16608, 1996.
5. Mosnier, L.O., von Dem Borne, P.A. Meijers, J.C., Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. *Thromb.Haemost.* **80**:829-835, 1998.
6. Juhan-Vague, I., Renucci, J.F., and Grimaux, M., Morange, P.E., Gouvernet, J., Gourmelin, Y., Laessi, M.C, Thrombin Activatable Fibrinolysis Antigen Levels and cardiovascular Risk Factors. *Arter.Thromb.Vascular.Biology.* **20**:2156-2161, 2000.

PRODUCT SPECIFICATIONS

Description:

Vial containing 0.120 ml of IgG purified by affinity chromatography on immobilized TAFI. Total protein is 0.5 mg.

Format:

Affinity-purified IgG (APIgG) clear liquid.

Host Animal:

Sheep

Immunogen:

Human TAFI purified from plasma.

Concentration:

APIgG concentration is 4.16 mg/ml, determined by absorbance using an extinction coefficient ($E_{280}^{1\%}$) of 13.4.

Buffer:

10 mM HEPES, 0.15 M NaCl, 50% (v/v) glycerol, pH 7.4..

Storage:

Store between -10 and -20 °C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.

Specificity:

This antibody is specific for TAFI as demonstrated by immunoelectrophoresis and ELISA.

Applications:

Suitable as a source of enriched antibodies to human TAFI.

Neutralizing activity:

Not determined.

Species Cross Reactivity:

Not determined.

RELATED PRODUCTS

SATAFI-IG Sheep anti-human TAFI, whole IgG from antiserum

SATAFI-HRP Sheep anti-human TAFI, IgG-peroxidase

TAFI-EIA Paired antibody set for ELISA, 4 x 96 wells

TAFI-DP Human plasma deficient in TAFI, immune depleted

Visit our site (www.enzymeresearch.co.uk) for further details.

Enzyme Research Laboratories Ltd

Glamorgan House . Charter Court . Enterprise Park . Swansea

SA7 9DD . UK

Tel: +44 (0)1792 686070

Email: info@enzymeresearch.co.uk

Website: www.enzymeresearch.co.uk